首页> 外文OA文献 >Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

【2h】

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

机译：卡培他滨联合奥沙利铂和贝伐单抗（AXELOX）作为适合和脆弱的转移性结直肠癌（mCRC）老年患者（年龄> 70岁）的一线治疗：希腊肿瘤研究组（HORG）的多中心II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lambros Vamvakas; Alexios Matikas; Athanasios Karampeazis; Dora Hatzidaki; Stelios Kakolyris; Charalampos Christophylakis; Ioannis Boukovinas; Aris Polyzos; Vassilis Georgoulias; John Souglakos;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. 奥沙利铂和卡培他滨联合贝伐单抗加放疗的新辅助方案治疗局部晚期直肠癌:单中心Ⅱ期研究结果 [J] . Xin Yu, De-sen Wan, Pei-rong Ding, 癌症（英文版） . 2018,第008期
2. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70?years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [J] . Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, BMC Cancer . 2014,第1期

机译：卡培他滨联合奥沙利铂和贝伐单抗（AXELOX）作为转移性结直肠癌（mCRC）的适应性和弱势老年患者（年龄> 70岁）的一线治疗：希腊肿瘤研究组（HORG）的多中心II期研究
3. Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer : A prospective, multicenter trial of the Korean cancer study group CO06-01 [J] . HongY.S., JungK.H., KimH.J., American Journal of Clinical Oncology: Cancer Clinical Trials . 2013,第6期

机译：卡培他滨联合或不联合奥沙利铂作为老年或脆弱转移性结直肠癌一线治疗的随机II期研究：韩国癌症研究组CO06-01的一项前瞻性，多中心试验
4. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged >= 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study) [J] . Nishina Tomohiro, Moriwaki Toshikazu, Shimada Mitsuo, Clinical colorectal cancer . 2016,第3期

机译：转移性结直肠癌的老年患者（年龄≥75岁）中的尿嘧啶-替加氟和口服白三叶素联合贝伐单抗：一项多中心，II期试验（贝伐单抗，口服白三叶素和尿嘧啶-替加氟联合治疗老年患者[J-BLUE ]研究）
5. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [O] . Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, 2014

机译：卡培他滨联合奥沙利铂和贝伐单抗（AXELOX）作为适合和脆弱的转移性结直肠癌（mCRC）老年患者（年龄 70岁）的一线治疗：希腊肿瘤研究组（HORG）的多中心II期研究
6. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [O] . Daniela Bianconi, Merima Herac, Florian Posch, 2020

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果，翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab，然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

著录项

引文网络

相似文献

相关主题

期刊订阅